EN DE
Watch Medicalg for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Medicalg (MDG) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Medicalg stock PLN 17.59, price PLN 21.40, that is 17.8% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare PL · ISIN PLMDCLG00015

M Medicalg logo Thin data Nov 13, 2026

Medicalg

MDG · WAR

Expensive (fair value 18% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +56% vs. a year ago. 
Fair value 17.59 PLN · Overvalued 
Quality 38/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −22.6 %/yr in PLN) 
Loss-making · -18.3% net margin (TTM) 
Negative free cash flow 
Trails peers (1/9) 
Narrow moat 15/100 · thin data
Thin data 
Estimate
Watch Medicalg for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

45.00 PLN 5.75 PLN Fair Value 17.59 PLN Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range 5.75 PLN – 45.00 PLN · fair‑value band 13.19 PLN – 21.98 PLN · the 21.40 PLN price screens above the 17.59 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow Medicalg in your weekly email

Every Wednesday you see whether Medicalg is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Medicalgorithmics S.A. provides cardiac diagnostic solutions in Poland, the United States, and internationally.

Show moreShow less

It offers PocketECG, an AI-driven online ECG monitoring device for long-term holter, cardiac event, and mobile cardiac telemetry analysis; Kardiobeat.ai, an AI-Driven lightweight wireless holter monitor; DeepRhythm Platform, a hardware-agnostic cloud-based software that leverages cutting-edge AI technology to detect, classify, analyze, and report ECG data; and DeepRhythmAI, a set of algorithms for heart rhythm analysis that integrates into third-party software and devices.

The company also provides virtual cardiac stress test (VCAST), an AI-based medical system developed for non-invasive, clinical quantitative, and qualitative analysis of CT-scan data, to assess the hemodynamic significance of coronary artery atherosclerotic stenosis.

In addition, it operates ECG TechBot, a software using a set of algorithms for automatic analysis and interpretation of the ECG signal based on deep learning methods.

In addition, the company engages in the provision of information technology and ECG monitoring services; research and development, including the development of artificial intelligence (AI) algorithms and software for arrhythmia diagnostics, as well as the development and commercialization of AI-based VCAST cardiac imaging technology; and production of electromedical equipment.

Medicalgorithmics S.A. company was incorporated in 2005 and is headquartered in Warsaw, Poland.

Stock analysis

Medicalg (MDG) currently trades at 21.40 PLN, while our estimate is 17.59 PLN, 18% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 13.19 PLN (bear) to 21.98 PLN (bull), the price of 21.40 PLN sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Medicalg reported revenue of 31.0M PLN in FY2025 versus 48.3M PLN in FY2021, a compound −10.5%/yr. Reported net income was −11.7M PLN in FY2025.

Key figures

Market cap 230M PLN (≈ $57.3M) Micro · P/S ratio 6.34 · EPS (TTM) −0.7000 PLN · Net margin −18.3% · Return on equity −10.5% · Return on assets (EBIT) −2.2% (5-year average) · Operating margin −0.1% · Revenue (TTM) 38.3M PLN.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 15 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at −18%, MDG screens richer than that median.

Fair Value

Bear 13.19 PLN Fair Value 17.59 PLN Bull 21.98 PLN
Price 21.40 PLN · Downside -17.8%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 12
How much profit the company makes from its sales and capital
Quality Growth 92
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 71
How calm the share price moves, does not count
Price momentum 13
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 40
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+29.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−20.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.6%
Start year 2020 (pandemic). Over 10 years: −4.5% a year
Revenue growth 15 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−33.6% (2020) → −26.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

MDG screens overvalued: fair value 18% below the price. Compare with Abbott Laboratories, →

Compare Medicalg with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −17.8% · Below median
Profitability
Return on assets −10.8% · Below median
Net margin (12 months) −18.3% · Below median
Operating margin (12 months) −0.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) 55.7% · Top 25%
Balance sheet
Debt / equity 0.27× · Above median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.55× · book value is mostly intangible assets ⓘGoodwill and other intangible assets (such as prices paid for past acquisitions, brands, licences or film and series rights) are larger than the equity. So we do not rank this P/B against the peer group.
P/S (12 months) 5.99× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)10 · sector 18
FUTURE (revenue growth)100 · sector 43
PAST (return on equity)0 · sector 0
HEALTH (low debt)87 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
DexCom, Inc DXCM $81.61 $91.66 +12% vs MDG
Boston Scientific Corporation BSX $43.69 $48.77 +12% vs MDG
Stryker Corporation SYK $310.72 $340.60 +10% vs MDG
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥185.38 ¥197.34 +6% vs MDG
GE HealthCare Technologies Inc GEHC $82.96 $69.92 −16% vs MDG
Siemens Healthineers AG SHL €43.30 €34.51 −20% vs MDG
Edwards Lifesciences Corporation EW $107.11 $81.94 −24% vs MDG
Medtronic plc MDT $102.88 $74.89 −27% vs MDG
Abbott Laboratories, ABT $107.45 $75.28 −30% vs MDG
Koninklijke Philips N.V PHIA €27.16 €15.23 −44% vs MDG

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Medicalg: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Medicalg Fair Value". https://www.fairvalue-calculator.com/stock/MDG

Frequently asked questions

Is Medicalg (MDG) overvalued or undervalued?
As of Nov 13, 2026, our estimate of fair value is 17.59 PLN versus a price of 21.40 PLN, about 18% lower (overvalued).
What is the fair value of MDG?
Our estimate for Medicalg is 17.59 PLN (as of Nov 13, 2026), built from audited fundamentals. The current price: 21.40 PLN.
What is the quality score of MDG?
Medicalg has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medicalg (MDG)?
Our calculated price target is the estimate of 17.59 PLN (as of Nov 13, 2026). Cautious scenario 13.19 PLN, optimistic scenario 21.98 PLN. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Medicalg stock forecast for 2026?
Our estimate puts fair value at 17.59 PLN, about 18% lower versus a price of 21.40 PLN (overvalued). Cautious scenario 13.19 PLN, optimistic scenario 21.98 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Medicalg (MDG)?
Medicalg reported trailing-twelve-month revenue of about 38.3M PLN (latest available figure, as of Nov 13, 2026).
What is the intrinsic value of Medicalg (MDG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medicalg it is 17.59 PLN per share (as of Nov 13, 2026), against a price of 21.40 PLN.
Is Medicalg stock overvalued or undervalued in 2026?
As of Nov 13, 2026, MDG trades above its calculated fair value: price 21.40 PLN, fair value 17.59 PLN, a gap of about −18% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of MDG?
No. The price is what the market pays today (21.40 PLN); the fair value is what the company's own numbers justify (17.59 PLN). For Medicalg the two are 3.81 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Medicalg worth?
The market values Medicalg at about 230M PLN (market capitalisation, as of Nov 13, 2026). Per share that is 21.40 PLN; our models calculate a fair value of 17.59 PLN per share.
What do the bullish and bearish scenarios say about MDG?
Our models span a range for Medicalg: cautious scenario 13.19 PLN, base 17.59 PLN, optimistic 21.98 PLN per share (as of Nov 13, 2026, price 21.40 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Medicalg (MDG)?
Balance-sheet figures for Medicalg (as of Nov 13, 2026): return on equity −10.5%, debt of 0.27 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is MDG from its 52-week high?
Medicalg trades at 21.40 PLN, about 42% below its 52-week high of 36.90 PLN and 5% above the low of 20.45 PLN (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of 17.59 PLN is for.
Which stocks are comparable to Medicalg?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medicalg stock attractive at the current price?
The data as of Nov 13, 2026: price 21.40 PLN, calculated fair value 17.59 PLN (−18%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Medicalg itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medicalg (MDG)?
The closing price on Nov 17, 2026 was 21.40 PLN. Our estimate is 17.59 PLN, about 18% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medicalg right now?
Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Medicalg

How large is the market capitalisation of Medicalg (MDG)?
The market capitalisation of Medicalg is 230M PLN (≈ $57.3M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medicalg (MDG)?
The price-to-sales ratio of Medicalg is 6.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medicalg (MDG)?
Earnings per share at Medicalg are −0.7000 PLN. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Medicalg (MDG)?
The net margin of Medicalg is −18.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Medicalg (MDG)?
The return on equity (ROE) of Medicalg is −10.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Medicalg (MDG)?
On an EBIT basis the return on assets of Medicalg is −2.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medicalg (MDG)?
The operating margin of Medicalg is −0.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medicalg (MDG)?
Revenue at Medicalg is growing 55.7% versus a year earlier (3y avg −20.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Medicalg (MDG) generate?
The free cash flow of Medicalg is −15.6M PLN (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Medicalg (MDG) carry?
The net debt of Medicalg is 16.2M PLN (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Medicalg in the live analysis

One click puts Medicalg on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.